Clinical Psychiatry News reports on Dr Donna M. Sudak, professor and director of the psychotherapy training program at Drexel University, Philadelphia, said during a premeeting workshop on high-yield brief CBT at the annual meeting of the American College of Psychiatrists.
Mara Cvejic, MD, a pediatric neurologist and sleep medicine fellow at the Stanford Center for Sleep Sciences and Medicine, shares the case study of an 8-year-old with Segawa’s disease with The Huffington Post.
Telltale signs in the brains of babies that have died of SIDS are remarkably similar to those of children who died of accidental asphyxiation, according to researchers at the University of Adelaide’s School of Medical Sciences.
A group of drugs commonly prescribed for insomnia, anxiety, and breathing issues “significantly increase the risk” that older people with chronic obstructive pulmonary disease (COPD) need to visit a doctor or emergency room for respiratory reasons, new research has found.
Lack of sleep in young fruit flies profoundly diminishes their ability to do one thing they do really, really well—make more flies, according to researchers at the Perelman School of Medicine at the University of Pennsylvania.
Fruit flies are pretty predictable when it comes to scheduling their days, with peaks of activity at dawn and dusk and rest times in between.
Children get more sleep, do better in school, behave better, and see other health benefits when parents limit content and the amount of time their children spend on the computer or in front of the TV. These are the findings of a new study, published in JAMA Pediatrics.
The University of Minnesota shares a story bout its Paul McCarron Sleep Medicine Fund.
As of this week, three new options are available for generic Sunovion Pharmaceuticals Inc’s Lunesta (eszopiclone), a pharmacological treatment for insomnia.
Hyderabad, India-based Dr. Reddy’s Laboratories has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg, and 3 mg, a therapeutic equivalent generic version of Lunesta (eszopiclone) tablets C-IV in the US market.